Everolimus Heart Transplant NDA Pending
This article was originally published in Pharmaceutical Approvals Monthly
A 12-month trial comparing concentration-controlled everolimus and reduced cyclosporine (Novartis' Neoral) to Pfizer's CellCept (mycophenolate mofetil) plus standard Neoral has been completed, according to ClinicalTrials.gov.
You may also be interested in...
Sponsors cannot cut corners in developing clinical data to support a revised dosing scheme, even when a drug’s efficacy has already been shown, Novartis learned while shepherding its kidney transplant agent Zortress (everolimus) through the FDA approval process.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011